Commercial Channels

The orphan drug will reach patients through a limited-distribution network of specialty pharmacies

The year-old-plus litigation highlights the value of customer master data

Alliance for Regenerative Medicine tries to rationalize how payers address economic value

Rare diseases are hard to treat; supporting the patient can be even more challenging

Leading US provider will produce 70 million doses in next several months

Tetraphase’s anticipated approval of an antibiotic will benefit from precise marketing targeting

The flood of new oncology drugs is challenging the ability of healthcare providers to determine best treatment choices

MyCubixx technology puts an interactive refrigerator in the patient’s home

PIM will eventually forge links from manufacturer to patient

‘End to end evidence management’ will affect both clinical and commercial activities

Today's smart, advanced self-injectable devices aim to provide therapeutic value to patient and physicians, and commercial value to the drug makers and payers

A double-digit growth rate through 2024 means boom times for drug-delivery devices and for contract manufacturing services

DIANA Awards for best product launches go to Alkermes and Mylan

Addition to its OCE platform enables collaboration between clients, agencies, sales ops

Will a combination of better diagnosis resources and cost cutting lead to better patient outcomes?

Center for Safe Internet Pharmacies builds a coalition to help families; looks into the ‘dark web’

Big Data and AI will bring value beyond compliance

Responsive. Flexible. Data-Driven.

… and will double again to $100 billion in 2022, says IQVIA

CRM data will be the first data type to be stored; Veeva CRM Suite also gets updated

Meeting and exhibition spans research, regulatory and commercial elements

More IT intelligence can reduce time to therapy for patient support

Questions raised over how prescription dosages translate into bulk consumption; IQVIA ‘stand(s) behind our data methodologies’

With new cellular and genetic therapies, the reimbursement process will need to evolve

Connecting with buying influences in integrated delivery networks is a challenge

14th edition attracted 59 commercial plans as respondents, representing 100 million lives

Company celebrates its growth at annual industry event

Specialty-pharma support providers have a potential benefit in behavioral targeting insights

Company offers a risk-mitigation analytics suite to enable pharma monitoring

While nominal spending was up 1.4%, actual net spending was only 0.6% greater than 2016